AMSBIO Introduces New Range of Human Stem Cell-Derived Neural Progenitors and Neurons for Research Areas Including Alzheimer’s Disease

AMSBIO has introduced a new range of neural progenitor cells, and cerebral cortical neurons, derived from human induced pluripotent stem (iPS) cells.

Despite the large investment and interest in neuroscience traditional methods of studying the human nervous system and disease pathogenesis and mechanisms required the generation of animal models. However, these methods are time consuming, costly and often fail to replicate the desired human pathologies and symptoms.

Using cutting-edge stem cell technologies to generate high purity human neural cells and neurons, AMSBIO is able to provide healthy and Alzheimer disease patient derived cerebral cortical neurons and neural progenitor cells. This accessible, in vitro human based system offers a platform to build human cellular models to study conditions including Alzheimer’s, autism, epilepsy, traumatic brain injury and stroke. Derived using integration-free fully defined neural induction conditions, these cells are electrically active, form functional synapses in vitro and can be transplanted into animal models.

Available in industrial quantities - AMSBIO cerebral cortical neurons and neural progenitor cells are supplied with extensive functional and molecular characterization data. All products are supplied ready-made and remain viable in culture for months to facilitate reproducible and long term studies. Cells from multiple donors are available for purchase allowing data comparison among biological replicates.

Alzheimer’s disease is the most common neurodegenerative disorder, now affecting over 24 million people worldwide. Predicted to reach 100 million by 2050, this technology platform has been focused on providing both healthy and Alzheimer’s disease relevant human neurons derived from iPS cells to complement existing studies of this condition.